Azilsartan — Discount Pricing

Other medications in Heart & Cardiovascular

• Bempedoic Acid
• Benazepril
• Bisoprolol
• Bosentan
• Bumetanide
• Candesartan
• Cangrelor
• Captopril

What Azilsartan is approved for (FDA label)

Azilsartan medoxomil tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with azilsartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: May 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Azilsartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue azilsartan medoxomil tablets as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue azilsartan medoxomil tablets as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )

Source: FDA prescribing information (DailyMed). Set ID: b1c8de43-3b26-408f-8c7e-6c7d76348199. SPL document ID: f05aba4d-376f-460f-9264-ecf267e04dcd. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Azilsartan (FDA label)

Azilsartan medoxomil tablets are supplied as white to off-white round tablets in the following dosage strengths: 40-mg tablets – debossed "J4" on one side and "L" on other side 80-mg tablets – debossed "J5" on one side and "L" on other side Tablets: 40 mg and 80 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: b1c8de43-3b26-408f-8c7e-6c7d76348199. SPL document ID: f05aba4d-376f-460f-9264-ecf267e04dcd. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Azilsartan (FDA label)

The most common adverse reaction in adults was diarrhea (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 4814 patients were evaluated for safety when treated with azilsartan medoxomil tablets at doses of 20, 40 or 80 mg in clinical trials.

Source: FDA prescribing information (DailyMed). Set ID: b1c8de43-3b26-408f-8c7e-6c7d76348199. SPL document ID: f05aba4d-376f-460f-9264-ecf267e04dcd. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Azilsartan (FDA label)

Do not coadminister aliskiren-containing products with azilsartan medoxomil tablets in patients with diabetes [see Drug Interactions ( 7 )] . Do not coadminister aliskiren-containing products with azilsartan medoxomil tablets in patients with diabetes. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: b1c8de43-3b26-408f-8c7e-6c7d76348199. SPL document ID: f05aba4d-376f-460f-9264-ecf267e04dcd. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Azilsartan (FDA label)

Correct volume or salt depletion prior to administration of azilsartan medoxomil tablets. ( 5.2 ) Monitor for worsening renal function in patients with renal impairment. ( 5.3 ) 5.1 Fetal Toxicity Azilsartan medoxomil tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure and death.

Source: FDA prescribing information (DailyMed). Set ID: b1c8de43-3b26-408f-8c7e-6c7d76348199. SPL document ID: f05aba4d-376f-460f-9264-ecf267e04dcd. Label effective date: May 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.